AIBOTICS Reports Zero Revenue, Worsening Liquidity, and Massive Dilution in Q1
AIBT sits 38% above its 52-week low of $0.001 on light trading volume (0.2× avg).
Summary
Aibotics, Inc. reported zero revenue and a worsening financial position in Q1 2026, alongside significant share dilution and reiterated 'going concern' and internal control warnings.
Key Events · Earnings and Guidance · AIBT
-
Zero Revenue Reported
The company generated no revenue for the three months ended March 31, 2026, down from $2,183 in the same period last year.
-
Worsening Liquidity and Going Concern
The working capital deficit increased to $4.72 million as of March 31, 2026, and the company reiterated its 'going concern' warning due to recurring losses and negative cash flows.
-
Significant Share Dilution
Aibotics issued approximately 52.4 million common shares for $98.2 thousand in Q1 2026, and an additional 142.5 million shares for $112.9 thousand in subsequent events, representing substantial dilution.
-
Multiple Debt Defaults
Several convertible notes payable, including those from Lender G (formerly Lender A), Lender B, and Lender E, are in default, with default interest accruing at 20%.
Analysis · AIBT · Life Sciences
Aibotics, Inc. reported zero revenue for the first quarter of 2026, a significant decline from $2,183 in the prior year, highlighting severe operational challenges. The company's financial position deteriorated further with a worsening working capital deficit of $4.72 million and increased cash burn from operations. The filing reiterates a 'going concern' warning and material weaknesses in internal controls, consistent with previous disclosures. To manage liquidity, the company engaged in highly dilutive financing activities, issuing approximately 52.4 million shares for $98.2 thousand in Q1 2026, and an additional 142.5 million shares for $112.9 thousand in subsequent events, representing a substantial portion of its market capitalization. Multiple convertible notes are in default, and a new equity incentive plan for 500 million shares signals potential for further significant dilution.
At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $510.9K. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.